Shopping Cart 0
Cart Subtotal
AED 0

Almac Group Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

Summary

Almac Group Ltd (Almac) is a contract development and manufacturing organization provides integrated services to pharmaceutical and biotechnology companies. The company offers a comprehensive range of services across the lifecycle of biopharmaceutical products which extend from research through pharmaceutical and clinical development to commercialization of products. Its services portfolio encompass diagnostics and biomarker development; clinical technologies; API (Active Pharmaceutical Ingriendient) services and chemical development; pharmaceutical development; analytical services; clinical services; and commercial services. The company operates through its subsidiaries in California, North Carolina and Pennsylvania in the US; and Singapore. Almac is headquartered in Craigavon, Northern Ireland, the UK.

Almac Group Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Almac Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Almac Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Almac Group Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Galen Acquires US Rights to ADASUVE from Alexza Pharma 12

Galen Acquires US Rights For Synera From Nuvo Research For USD14.5 Million 13

Almac Acquires Noack N 623 Blister Packaging Line From Romaco Pharma 14

Galen Acquires DaunoXome, Chemotherapy Agent, From Gilead Sciences 15

Partnerships 17

Genomic Health Enters Into In-Licensing Agreement With Almac To Develop And Commercialize Anthracycline Chemotherapy Benefit Test 17

Almac Discovery and Royal College of Surgeons in Ireland Enter into Research Agreement 19

McClay Foundation, Almac Discovery and University of Ulster Enter into Research Agreement 20

Elasmogen and Almac Discovery Enter into Co-Development Agreement 21

Almac Discovery Enters Into Agreement With Queen's University Belfast For Drug Discovery 22

Almac Enters Into Co-Development Agreement With University College London For Metagenomics, Enzyme Discovery Tools 24

Almac Enters Into Distribution Agreement With Affymetrix For Xcel Array 25

Licensing Agreements 26

Debiopharm International Enters into Licensing Agreement with Almac Discovery 26

Genentech Enters into Licensing Agreement with Almac Discovery 27

Galen Enters Into Licensing Agreement With Medical Developments International For Penthrox 28

Almac Discovery Enters Into Licensing Agreement With Shin Poong Pharma For ALM201 29

Acquisition 30

Almac Acquires 100% Stake in Bioclin Research Laboratories 30

Almac Group Acquires Arran Chemical 31

Almac Group Ltd-Key Competitors 32

Almac Group Ltd-Key Employees 33

Almac Group Ltd-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Recent Developments 37

Strategy And Business Planning 37

Oct 10, 2018: Almac Group invests to expand its existing North Carolina Facility 37

Feb 28, 2018: Almac Group Expands with Opening of GBP20 million Cold Chain Facility 38

Jan 26, 2018: Almac Group Announces Further Global Expansion as it Secures New Premises in Republic of Ireland 39

Jan 24, 2018: Almac Group Launches Bespoke Elemental Impurities Laboratory 40

Jan 09, 2017: Almac Group Launches Almac Clinical University 41

Financial Announcements 42

Jun 04, 2018: Almac Group turnover surpasses GBP500 million for first time 42

Corporate Communications 43

Aug 27, 2018: Almac Group appoints new site head for Charnwood Campus, Loughborough, UK 43

Legal and Regulatory 44

Oct 02, 2018: Almac Group announces successful HPRA inspection at its European campus 44

Jul 27, 2018: Almac Group launches GMP high throughput peptide manufacturing service 45

Jan 18, 2018: Almac Group announces further expansion at its European Campus in Dundalk 46

Oct 23, 2017: Almac Group Announces Successful MHRA Inspection at Charnwood Facilities 47

Product News 48

Jan 30, 2017: Almac Group Launches Next Generation Temperature Management Software 48

Other Significant Developments 49

Oct 09, 2018: Arran Chemical Company Completes Stage II of its Strategic Plan ADAPT 49

Jul 16, 2018: Almac Group Invests in NMR Equipment to Enhance Existing Analytical Services Capability 50

Jun 07, 2017: Almac Group Reports Pre-tax Profits of GBP27M 51

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Almac Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Almac Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Almac Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Almac Group Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Almac Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Galen Acquires US Rights to ADASUVE from Alexza Pharma 12

Galen Acquires US Rights For Synera From Nuvo Research For USD14.5 Million 13

Almac Acquires Noack N 623 Blister Packaging Line From Romaco Pharma 14

Galen Acquires DaunoXome, Chemotherapy Agent, From Gilead Sciences 15

Genomic Health Enters Into In-Licensing Agreement With Almac To Develop And Commercialize Anthracycline Chemotherapy Benefit Test 17

Almac Discovery and Royal College of Surgeons in Ireland Enter into Research Agreement 19

McClay Foundation, Almac Discovery and University of Ulster Enter into Research Agreement 20

Elasmogen and Almac Discovery Enter into Co-Development Agreement 21

Almac Discovery Enters Into Agreement With Queen's University Belfast For Drug Discovery 22

Almac Enters Into Co-Development Agreement With University College London For Metagenomics, Enzyme Discovery Tools 24

Almac Enters Into Distribution Agreement With Affymetrix For Xcel Array 25

Debiopharm International Enters into Licensing Agreement with Almac Discovery 26

Genentech Enters into Licensing Agreement with Almac Discovery 27

Galen Enters Into Licensing Agreement With Medical Developments International For Penthrox 28

Almac Discovery Enters Into Licensing Agreement With Shin Poong Pharma For ALM201 29

Almac Acquires 100% Stake in Bioclin Research Laboratories 30

Almac Group Acquires Arran Chemical 31

Almac Group Ltd, Key Competitors 32

Almac Group Ltd, Key Employees 33

Almac Group Ltd, Other Locations 34

Almac Group Ltd, Subsidiaries 34

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Summary

Almac Group Ltd (Almac) is a contract development and manufacturing organization provides integrated services to pharmaceutical and biotechnology companies. The company offers a comprehensive range of services across the lifecycle of biopharmaceutical products which extend from research through pharmaceutical and clinical development to commercialization of products. Its services portfolio encompass diagnostics and biomarker development; clinical technologies; API (Active Pharmaceutical Ingriendient) services and chemical development; pharmaceutical development; analytical services; clinical services; and commercial services. The company operates through its subsidiaries in California, North Carolina and Pennsylvania in the US; and Singapore. Almac is headquartered in Craigavon, Northern Ireland, the UK.

Almac Group Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Almac Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Almac Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Almac Group Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Galen Acquires US Rights to ADASUVE from Alexza Pharma 12

Galen Acquires US Rights For Synera From Nuvo Research For USD14.5 Million 13

Almac Acquires Noack N 623 Blister Packaging Line From Romaco Pharma 14

Galen Acquires DaunoXome, Chemotherapy Agent, From Gilead Sciences 15

Partnerships 17

Genomic Health Enters Into In-Licensing Agreement With Almac To Develop And Commercialize Anthracycline Chemotherapy Benefit Test 17

Almac Discovery and Royal College of Surgeons in Ireland Enter into Research Agreement 19

McClay Foundation, Almac Discovery and University of Ulster Enter into Research Agreement 20

Elasmogen and Almac Discovery Enter into Co-Development Agreement 21

Almac Discovery Enters Into Agreement With Queen's University Belfast For Drug Discovery 22

Almac Enters Into Co-Development Agreement With University College London For Metagenomics, Enzyme Discovery Tools 24

Almac Enters Into Distribution Agreement With Affymetrix For Xcel Array 25

Licensing Agreements 26

Debiopharm International Enters into Licensing Agreement with Almac Discovery 26

Genentech Enters into Licensing Agreement with Almac Discovery 27

Galen Enters Into Licensing Agreement With Medical Developments International For Penthrox 28

Almac Discovery Enters Into Licensing Agreement With Shin Poong Pharma For ALM201 29

Acquisition 30

Almac Acquires 100% Stake in Bioclin Research Laboratories 30

Almac Group Acquires Arran Chemical 31

Almac Group Ltd-Key Competitors 32

Almac Group Ltd-Key Employees 33

Almac Group Ltd-Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Recent Developments 37

Strategy And Business Planning 37

Oct 10, 2018: Almac Group invests to expand its existing North Carolina Facility 37

Feb 28, 2018: Almac Group Expands with Opening of GBP20 million Cold Chain Facility 38

Jan 26, 2018: Almac Group Announces Further Global Expansion as it Secures New Premises in Republic of Ireland 39

Jan 24, 2018: Almac Group Launches Bespoke Elemental Impurities Laboratory 40

Jan 09, 2017: Almac Group Launches Almac Clinical University 41

Financial Announcements 42

Jun 04, 2018: Almac Group turnover surpasses GBP500 million for first time 42

Corporate Communications 43

Aug 27, 2018: Almac Group appoints new site head for Charnwood Campus, Loughborough, UK 43

Legal and Regulatory 44

Oct 02, 2018: Almac Group announces successful HPRA inspection at its European campus 44

Jul 27, 2018: Almac Group launches GMP high throughput peptide manufacturing service 45

Jan 18, 2018: Almac Group announces further expansion at its European Campus in Dundalk 46

Oct 23, 2017: Almac Group Announces Successful MHRA Inspection at Charnwood Facilities 47

Product News 48

Jan 30, 2017: Almac Group Launches Next Generation Temperature Management Software 48

Other Significant Developments 49

Oct 09, 2018: Arran Chemical Company Completes Stage II of its Strategic Plan ADAPT 49

Jul 16, 2018: Almac Group Invests in NMR Equipment to Enhance Existing Analytical Services Capability 50

Jun 07, 2017: Almac Group Reports Pre-tax Profits of GBP27M 51

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Almac Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Almac Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Almac Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Almac Group Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Almac Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Almac Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Galen Acquires US Rights to ADASUVE from Alexza Pharma 12

Galen Acquires US Rights For Synera From Nuvo Research For USD14.5 Million 13

Almac Acquires Noack N 623 Blister Packaging Line From Romaco Pharma 14

Galen Acquires DaunoXome, Chemotherapy Agent, From Gilead Sciences 15

Genomic Health Enters Into In-Licensing Agreement With Almac To Develop And Commercialize Anthracycline Chemotherapy Benefit Test 17

Almac Discovery and Royal College of Surgeons in Ireland Enter into Research Agreement 19

McClay Foundation, Almac Discovery and University of Ulster Enter into Research Agreement 20

Elasmogen and Almac Discovery Enter into Co-Development Agreement 21

Almac Discovery Enters Into Agreement With Queen's University Belfast For Drug Discovery 22

Almac Enters Into Co-Development Agreement With University College London For Metagenomics, Enzyme Discovery Tools 24

Almac Enters Into Distribution Agreement With Affymetrix For Xcel Array 25

Debiopharm International Enters into Licensing Agreement with Almac Discovery 26

Genentech Enters into Licensing Agreement with Almac Discovery 27

Galen Enters Into Licensing Agreement With Medical Developments International For Penthrox 28

Almac Discovery Enters Into Licensing Agreement With Shin Poong Pharma For ALM201 29

Almac Acquires 100% Stake in Bioclin Research Laboratories 30

Almac Group Acquires Arran Chemical 31

Almac Group Ltd, Key Competitors 32

Almac Group Ltd, Key Employees 33

Almac Group Ltd, Other Locations 34

Almac Group Ltd, Subsidiaries 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com